Table 1.
Baseline characteristics.
| Characteristic | Patient | |
|---|---|---|
| 1 | 2 | |
| Age (years) | 69 | 62 |
| Sex | Male | female |
| ECOG | 1 | 0 |
| Prior therapies | (1) VAD | (1) VAD |
| (2) PAD | (2) PAD | |
| (3) PID | (3) VMD | |
| (4) Len+ DXM | ||
| (5) Len+ DXM+ CTX | ||
| Prior lines of therapy | 3 | 5 |
| Relapsed/refractory status | Refractory second or higher line of therapy | Refractory third line of therapy |
| Primary diagnosis/sub-type | MM IgD-λ | MM IgA-κ |
| Durie-Salmon | IIIA | IA |
VAD, vincristine, doxorubicin, dexamethasone; PAD, bortezomib, doxorubicin, dexamethasone; PID, bortezomib, idarubicin, dexamethasone; CTX, Cyclophosphamide; Len, lenalidomide.